Infliximab
Treatment for Inflammatory Bowel Disease
Typical Dosage: 5 mg/kg IV every 8 weeks
Effectiveness
83%
Safety Score
55%
Clinical Trials
259
Participants
50K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
55
DangerousModerateSafe
Treatment Details
Dosage Range
5 mg/kg IV every 8 weeks
Time to Effect
2-4 weeks
Treatment Duration
lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
3(Treat 3 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
40(Treat 40 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$25,000
Monitoring:$3,000
Side Effect Mgmt:$1,500
Total Annual:$29,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$180,000/QALY
QALYs Gained
0.3
Outcome-Based Costs
Cost per Responder
$45,385
Cost per Remission
$84,286
Comparison vs Azathioprine
Cost Difference
+$28,000/year
More expensive
QALY Difference
+0.15 QALYs
Better outcomes
Dominance
No dominance
Active Clinical Trials
3 active trials recruiting for Infliximab in Inflammatory Bowel Disease
Subcutaneous Infliximab After A Previous Intravenous Dose Optimization
NCT06113913RECRUITINGPHASE4
275 participants
INTERVENTIONAL
Ghent, Belgium +14 more
Started: Apr 9, 2024
Comparison of Ustekinumab, Infliximab and Combination Therapy in Moderately to Severely Active Ulcerative Colitis
NCT06453317RECRUITINGPHASE2
172 participants
INTERVENTIONAL
Lodz, Poland
Started: Feb 17, 2025
Proactive Infliximab Optimization Using a Pharmacokinetic Dashboard Versus Standard of Care in Patients With Inflammatory Bowel Disease: The OPTIMIZE Trial
NCT04835506ENROLLING BY INVITATIONPHASE4
124 participants
INTERVENTIONAL
New Haven, United States +24 more
Started: Nov 1, 2021
Completed Clinical Trials
11 completed trials for Infliximab in Inflammatory Bowel Disease
Model-informed Dose De-escalation of Infliximab in Patients With Inflammatory Bowel Diseases
NCT04982172COMPLETEDPHASE4
80 participants
INTERVENTIONAL
Leuven, Belgium
Started: Feb 8, 2022
Safety of Reduced Infliximab Infusion Time
NCT05340764COMPLETEDPHASE4
96 participants
INTERVENTIONAL
St Louis, United States
Started: Aug 1, 2020
Infliximab and Adalimumab in Inflammatory Bowel Disease Patients.
NCT05291039COMPLETEDNA
56 participants
INTERVENTIONAL
Cairo, Egypt
Started: Jan 1, 2022
Abdominal Ultrasound With Doppler and Peripheral Hemogram in Assesment Inflammatory Bowel Disease
NCT03445624COMPLETED
60 participants
OBSERVATIONAL
Asyut, Egypt
Started: Jul 1, 2018
Biomarkers of Anti-TNF Treatment in Inflammatory Bowel Disease (IBD)
NCT01971970COMPLETED
45 participants
OBSERVATIONAL
Rotterdam, Netherlands
Started: Oct 1, 2013
Anti-TNF Therapy for Refractory Colitis in Hospitalized Children
NCT02799615COMPLETED
38 participants
OBSERVATIONAL
Hartford, United States +6 more
Started: May 1, 2016
IDeaL Pilot Study - Infliximab Dose to Level: Pilot Study
NCT02847884COMPLETED
28 participants
OBSERVATIONAL
Edmonton, Canada +1 more
Started: Oct 1, 2015
Comparison Between Infliximab and Adalimumab on Patients With Ulcerative Colitis
NCT06269185COMPLETED
271 participants
OBSERVATIONAL
Gothenburg, Sweden
Started: Mar 6, 2024
Precision Dosing of Infliximab Versus Conventional Dosing of Infliximab
NCT02453776COMPLETEDPHASE4
80 participants
INTERVENTIONAL
Amsterdam, Netherlands
Started: May 1, 2015
Post-Marketing Use Of CT-P13 (Infliximab) For Standard Of Care Treatment Of Inflammatory Bowel Disease
NCT02539368COMPLETED
2.56K participants
OBSERVATIONAL
Leuven, Belgium +139 more
Started: Apr 22, 2015
Comparison of Capso Vision SV-1 to PillCam SB2 in the Evaluation of Subjects With Suspected Small Bowel Disease
NCT01787825COMPLETEDNA
121 participants
INTERVENTIONAL
Scottsdale, United States +6 more
Started: May 1, 2012
Showing 20 of 261 total trials